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Purpose: Refractory ascites (RA) is closely related to a high morbidity and mortali-
ty. In this study, we investigated predictors of RA development in patients with hep-
atitis B virus (HBV)-related cirrhosis who were hospitalized to control ascitic de-
compensation, and determined predictors for survival in patients who experienced 
RA. Materials and Methods: We analyzed 199 consecutive patients with HBV-re-
lated cirrhosis who were hospitalized to control ascitic decompensation between 
January 1996 and December 2008. Results: Multivariate analyses showed that only 
serum potassium at admission predicted RA development independently [p=0.013; 
hazard ratio (HR), 2.800; 95% confidence interval (CI), 1.166-6.722]. During the 
follow-up period, 16 (8.0%) patients experienced RA within 4.2 (range, 1.0-39.2) 
months after admission for controlling ascitic decompensation, and they survived a 
median of 8.7 (range, 3.9-51.3) months. Child-Pugh class and RA type were identi-
fied as independent prognostic factors affecting the survival in patients with RA 
(p=0.045; HR, 8.079; 95% CI, 1.231-67.984 and p=0.013; HR, 14.510; 95% CI, 
1.771-118.874, respectively). Conclusion: Serum potassium was an independent 
predictor of RA development in patients with HBV-related cirrhosis who were hos-
pitalized to control ascitic decompensation. After RA development, Child-Pugh 
class and RA type were independent predictors for survival.
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INTRODUCTION
Ascitic decompensation is a common major complication of cirrhosis and a sign of 
advanced liver disease because the prognosis becomes poorer after ascitic decom-
pensation.1-3 Once cirrhosis is clinically confirmed, nearly 60% of patients experi-
ence ascitic decompensation within 10 years,4 and eventually ascites becomes re-
sistant to medical treatments in 5-10% of the patients,5 which is called refractory 
ascites (RA). A significant increase in sodium excretion cannot be achieved be-
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hepatorenal syndrome (HRS) at the time of admission and 
those with ascites caused by nephrogenic causes, tuberculo-
sis, or malignancy. Patients with intra-abdominal malignan-
cies, including hepatocellular carcinoma (HCC), at the time 
of admission, and those who underwent liver transplanta-
tion during the follow-up period were also excluded from 
the statistical analysis to exclude the possible confounding 
effects on the disease course.
We investigated age, gender, Child-Pugh class, past his-
tory of HE, comorbid disorders, complications at admission 
and during hospitalization, antiviral treatment, and performed 
serologic tests and ascitic fluid examinations. HBV DNA 
levels were measured using Digene Hybrid Capture assay 
(Digene, Gaithersburg, MD, USA), which has a lower de-
tection limit of 141500 copies/mL. For patients who devel-
oped RA during the follow-up period, we checked also the 
type of RA, treatment modalities for RA, and amount of al-
bumin infusion.
Diagnosis of ascites and RA
The diagnosis of ascites was made based on physical exam-
ination, ultrasonography or computed tomography results, 
and that of RA according to the International Ascites Club 
diagnostic criteria5 as follows: “ascites that cannot be mobi-
lized, or early recurrence of ascites which cannot be satis-
factorily prevented by medical therapy”. Accordingly, there 
were two types of RA: “diuretic-intractable ascites” which 
could not be mobilized or its early recurrence could not be 
prevented because the development of diuretic-induced 
complications such as hyperkalemia, hypokalemia, hypona-
tremia, HE, or renal failure precluded the use of an effec-
tive diuretic dosage, and “diuretic-resistant ascites”, which 
is induced by failure of a significant increase in sodium ex-
cretion because patients do not respond to high doses of di-
uretics (spironolactone 400 mg/day and furosemide 160 
mg/day) and sodium restriction.5
Definitions of liver-related complications
The definitions of liver-related complications were as fol-
lows: 1) spontaneous bacterial peritonitis (SBP) was defined 
as more than 250 polymorphonuclear cells/mm3 in the ascit-
ic fluid with no evidence of secondary peritonitis, accompa-
nied by fever and abdominal pain,2,3 2) renal failure was de-
fined as acute or chronic renal failure, but not HRS,11,12 3) 
gastrointestinal variceal bleeding was endoscopically con-
firmed, 4) HE was defined as personality changes, intellec-
tual impairment, and a depressed level of consciousness,13 5) 
cause patients with RA either do not respond to a high dose 
of diuretics or they suffer from side effects related to the use 
of diuretics, such as hyperkalemia, hyponatremia, hepatic 
encephalopathy (HE), and renal failure. Thus, RA is closely 
related to high morbidity and mortality with a 2-year surviv-
al rate of less than 50%.6
To date, large volume paracentesis, peritoneo-venous 
shunt, and transjugular intra-hepatic portosystemic shunt 
(TIPS), combined with diuretics, have widely been used to 
control ascites by reducing portal pressure and improving 
renal sodium excretion in patients with RA, so as to im-
prove their quality of life and help ease the waiting time 
for liver transplantation.7-9 However, these interventions 
have failed to significantly improve survival, and the prog-
nosis of RA has been demonstrated to be related more to 
the severity of underlying liver disease, regardless of treat-
ment modalities. Thus, liver transplantation has been 
strongly recommended for patients with RA to improve 
survival.10
Consequently, it is meaningful to investigate predictors 
of RA development in cirrhotic patients with ascitic de-
compensation, because these patients will benefit from 
prompt liver transplantation. However, there have been 
few investigations identifying predictors of RA develop-
ment in cirrhotic patients. Thus, the primary aim of our 
present study was to identify predictors of RA develop-
ment in patients with hepatitis B virus (HBV)-related cir-
rhosis who were hospitalized to control ascitic decompen-
sation, and the secondary aim was to determine predictors 
for the survival of patients who experienced RA during the 
follow-up period.
MATERIALS AND METHODS
　　　
Patient characteristics
This study included 199 consecutive patients with HBV-re-
lated cirrhosis who were admitted to Severance Hospital, 
Yonsei University, Seoul, Korea, for controlling ascitic de-
compensation between January 1996 and December 2008. 
The study population had received oral diuretics for a median 
of 28.2 (range, 0.3-41.4) months before admission. Our study 
protocol was in compliance with the ethical guidelines of the 
1975 Declaration of Helsinki. This retrospective study was 
approved by the institutional review board of our institute.
We excluded patients with concomitant hepatic decom-
pensation such as HE, gastrointestinal variceal bleeding, or 
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RESULTS
 
Baseline characteristics
Baseline characteristics of 199 patients hospitalized to con-
trol ascitic decompensation are shown in Table 1. Of them, 
136 (68.3%) patients were males, and the mean age of all 
patients was 52.9 years. SBP was the most common com-
plication at admission (n=27, 13.6%), and concomitant in-
fections (pneumonia, urinary tract infection, and sepsis) 
other than SBP were noted in 3 (1.5%) patients at admis-
sion. Seventy (35.2%) patients showed detectable HBV 
DNA and the median HBV DNA level in these patients was 
1094520 (range, 141910-28422420) copies/mL. Of these, 
49 patients received antiviral treatment using nucleos(t)ide 
analogs.
Between patients with and without RA development, 
there were no significant differences in baseline characteris-
tics. However, the proportion of previous history of HE and 
serum potassium level had a trend to be higher in patients 
with RA development (25.0 vs. 8.7%; p=0.061 and 4.4±0.8 
vs. 4.1±0.6 mEq/L; p=0.063).
Follow-up and survival
All follow-ups were discontinued on March 30, 2009 with 
a median follow-up period of 108.9 (range, 12.0-159.6) 
months after admission for controlling ascitic decompensa-
tion. The median survival of all patients was 10.7 (range, 
0.3-158.8) months. During the follow-up period, 16 (8.0%) 
patients experienced RA within 4.2 (range, 1.0-39.2) months 
(13 patients within 1 year, 1 between 1-2 years, 1 between 
2-3 years, and 1 between 3-4 years) and they survived a 
median of 8.7 (range, 3.9-51.3) months after RA develop-
ment. The cumulative 1-, 2-, and 3-year survival rates after 
RA development were 25.0%, 18.8% and 12.5%, respec-
tively. During the study period, 15 (7.5%) patients experi-
enced HCC development.
Predictors of RA development
Table 2 shows the univariate and subsequent multivariate 
analyses that were performed to identify independent predic-
tors of RA development. A previous history of HE, serum so-
dium, and serum potassium was selected as significant vari-
ables in univariate analysis associated to RA development. 
However, subsequent multivariate analysis using these three 
variables showed that serum potassium was the only inde-
pendent predictor of RA development in patients with HBV-
HRS was defined according to the International Ascites 
Club diagnostic criteria,5 and 6) liver failure was defined as 
rapid deterioration of liver function, resulting in coagulopa-
thy, usually an international normalized ratio greater than 
1.5 and any degree of HE.14
Treatment strategies
Ascites was managed with diuretics or intermittent para-
centesis with cautions to prevent the increase of the previ-
ous serum creatinine level by more than 50% after ascites 
management.5 Patients with grade 2 or moderate ascites 
were treated with salt restriction (Na+ 30-50 mmol, 1600-
2400 kcal/day) and a progressive dose of spironolactone 
alone or with furosemide (starting dose: furosemide 0-40 
mg/day, spironolactone 50-100 mg/day; maintenance dose: 
furosemide 0-160 mg/day, spironolactone 50-400 mg/day). 
Patients with grade 3 or tense ascites were treated with ad-
ditional albumin replacement, therapeutic paracentesis, 
peritoneo-venous shunt, or TIPS.1
RA development and survival analysis
RA development was used as an event to calculate predic-
tors of RA development. For all patients, death was the end-
point of follow-up. The overall survival time was calculated 
from the date of admission for controlling ascitic decom-
pensation to death. Additionally, the survival time from the 
date of RA diagnosis to death was also calculated in months 
for patients who experienced RA during the follow-up peri-
od, and predictors for survival were also investigated in 
these patients.
Statistical analyses
Results of continuous variables are presented as means± 
standard deviation, and those of categorical variables as 
numbers (%). Student’s t-test (or Mann-Whitney U test) and 
the chi-squared test (or Fisher’s exact test) were used to 
compare quantitative and qualitative variables, respectively. 
Cumulative probability of RA development and cumulative 
survival of patients with RA were estimated according to the 
Kaplan-Meier method. To identify independent predictors of 
RA development and predictors for survival in patients with 
RA, variables that achieved a p-value <0.1 in univariate 
analyses were included in a multivariate analysis, based on a 
proportional hazards Cox regression model. Hazard ratio 
(HR) and corresponding 95% confidence intervals (CI) were 
calculated. All data analyses were conducted using the SPSS 
software (ver. 16.0; SPSS, Chicago, IL, USA).
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our study population (4.1 mEq/L; sensitivity 68.7%, speci-
ficity 54.6%, positive predictive value 11.6%, and negative 
predictive value 95.3%) as a cutoff value, RA development 
related cirrhosis who were hospitalized to control ascitic de-
compensation (p=0.013; HR, 2.800; 95% CI, 1.166-6.722).
When we selected the mean serum potassium level of 
Table 1. Baseline Characteristics of Patients with HBV-Related Liver Cirrhosis Who Were Hospitalized to Control Ascitic De-
compensation at Admission (n=199)
Variables Total (n=199)
Patients without RA 
development 
(n=183, 92.0%)
Patients with RA 
development 
(n=16, 8.0%)
p value
Age (yrs) 52.9±10.3  52.7±10.4 55.7±9.7 0.272
Male  136 (68.3) 123 (67.2) 13 (81.3) 0.281
Child-Pugh class B/C 75 (37.7)/124 (62.3) 71 (38.8)/112 (61.2) 4 (25.0)/12 (75.0) 0.510
Previous history of HE   20 (10.0) 16 (8.7)   4 (25.0) 0.061
Antiviral treatment   49 (24.6)   45 (24.6)   4 (25.0) 0.525
Detectable HBV DNA   70 (35.2)   66 (36.1)   4 (25.0) 0.883
Comorbidity
    Diabetes mellitus   25 (12.6)   24 (13.1) 1 (6.3) 0.498
    Pulmonary disease* 10 (5.5)   9 (4.9) 1 (6.3) 0.576
    Cardiovascular disease†   9 (4.5)   7 (3.8)   2 (12.5) 0.786
Complications at admission 
    Spontaneous bacterial peritonitis   27 (13.6)   26 (14.2) 1 (6.3) 0.483
    Infection‡   3 (1.5)   3 (1.6) 0 (0.0) 0.777
    Renal failure§   21 (10.6)   20 (10.9) 1 (6.3) 0.706
Complications during hospitalization
    Variceal bleeding   6 (3.0)   5 (2.7) 1 (6.3) 0.399
    Hepatic encephalopathy   9 (4.5)   9 (4.9) 0 (0.0) 0.610
    Spontaneous bacterial peritonitis   5 (2.5)   4 (2.2) 1 (6.3) 0.345
    Liver failure||  10 (5.0) 10 (5.5) 0 (0.0) 0.610
    Infection‡   3 (1.5)   2 (1.1) 1 (6.3) 0.223
    Hepatorenal syndrome   4 (2.0)   4 (2.2) 0 (0.0) 0.713
Serum
    Platelet count (×103/mm3) 83.9±48.4  84.9±50.2   66.8±22.5 0.179
    Albumin (g/dL) 2.7±0.4  2.7±0.4   2.6±0.4 0.478
    Alanine aminotransferase (IU/L)   71.8±109.1    70.0±101.7     93.9±176.2 0.400
    Prothrombin time (INR) 2.0±1.1  2.0±1.1   1.9±0.5 0.595
    Total bilirubin (mg/dL) 5.5±5.8  5.5±6.0   5.0±3.9 0.773
    Creatinine (mg/dL) 1.1±0.8  1.1±0.8   1.0±0.2 0.474
    Sodium (mEq/L) 134.1±5.7 134.3±5.7 132.6±5.9 0.272
    Potassium (mEq/L) 4.1±0.7  4.1±0.6   4.4±0.8 0.063
Ascitic fluid
    WBC count (×103/mm3) 1.2±4.0  1.2±4.2   0.6±1.0 0.573
    Protein (g/dL) 1.0±0.8  1.0±0.9   0.9±0.4 0.717
    Albumin (g/dL) 0.5±0.3  0.5±0.3   0.5±0.2 0.825
    SAAG (g/dL) 2.2±0.4  2.2±0.5   2.1±0.3 0.705
    Follow-up period (months)        108.9 (12.0-159.6)        109.6 (33.2-159.6)      100.3 (12.0-150.6) 0.624
HBV, hepatitis B virus; HE, hepatic encephalopathy; INR, international normalized ratio; WBC, white blood cell; SAAG, serum ascites albumin gradient.
Variables are expressed as mean±SD, median (range), or n (%).
*Pulmonary disease included pulmonary tuberculosis, chronic obstructive pulmonary disease, and asthma.
†Cardiovascular disease included hypertension and congestive heart failure.
‡Infection included pneumonia, urinary tract infection, and sepsis.
§Renal failure was defined as acute or chronic renal failure, but not hepatorenal syndrome.
||Liver failure was defined as rapid deterioration of liver function results in coagulopathy, usually an INR greater than 1.5 and any degree of HE.
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dence rates of RA were 81.8%, 100%, and 100%, respec-
tively, in patients with serum potassium ≥4.1 mEq/L where-
as they were 38.2%, 60.4%, and 100%, respectively, in 
was significantly higher in patients with serum potassium 
≥4.1 mEq/L than those with <4.1 mEq/L (log-rank test, 
p=0.011) (Fig. 1). The 1-, 2-, and 3-year cumulative inci-
Table 3. Clinical Characteristics of Patients in Whom Refractory Ascites Developed during Follow-Up Period (n=16)
Variables Total (n=16) Alive (n=4) Dead (n=12) p value
Age (yrs) 55.7±9.7 61.3±5.8 53.8±8.6 0.194
Male 13 (81.3)   3 (75.0) 10 (83.3) 0.607
Child Pugh class B/C 4 (25.0)/12 (75.0) 3 (75.0)/1 (25.0) 1 (8.3)/11 (91.7) 0.027
Antiviral treatment   4 (25.0)   1 (25.0)   3 (25.0) 0.504
Detectable HBV DNA   4 (25.0)   2 (50.0)   2 (16.7) 0.912
Refractory ascites type 0.245
    Diuretic-resistant 11 (68.7)  4 (100)   7 (58.3)
    Diuretic-intractable   5 (31.3) 0 (0.0)   5 (41.7)
Treatment modality 0.268
    Paracentesis   2 (12.5)   1 (25.0) 1 (8.3)
    Portosystemic shunt procedure*   6 (37.5) 0 (0.0)   6 (50.0)
    TIPS   8 (50.0)   3 (75.0)   5 (41.7)
Complications at the time of RA development 
    Hyponatremia   7 (43.8)   2 (50.0)   5 (41.7) 0.608
    Metabolic acidosis   4 (25.0)   2 (50.0)   2 (16.7) 0.245
    Hepatorenal syndrome   3 (18.8) 0 (0.0)   3 (25.0) 0.529
    Renal failure†   5 (31.3)   1 (25.0)   4 (33.3) 0.635
Serum  
    Platelet count (×103/mm3) 66.8±22.5   81.3±29.7   63.3±19.0 0.173
    Albumin (g/dL) 2.6±0.4   2.8±0.3   2.5±0.4 0.317
    Alanine aminotransferase (IU/L)   93.9±176.2   44.5±39.9   110.3±201.8 0.536
    Prothrombin time (INR) 1.9±0.5   1.6±0.4   2.0±0.6 0.218
    Total bilirubin (mg/dL) 5.0±3.9   2.1±0.5   6.0±4.0 0.080
    Creatinine (mg/dL) 1.0±0.2   1.0±0.3   1.0±0.2 0.726
    Sodium (mEq/L) 132.6±5.9 130.0±7.7 133.4±5.0 0.320
    Potassium (mEq/L) 4.4±0.8   4.7±0.6   4.3±0.9 0.326
Ascitic fluid analysis 
    WBC count (×103/mm3) 0.6±1.0   1.2±1.5   0.4±0.8 0.389
    Protein (g/dL) 0.9±0.4   0.8±0.4   1.0±0.5 0.460
    Albumin (g/dL) 0.5±0.2   0.5±0.1   0.5±0.3 0.847
    SAAG 2.1±0.3   2.3±0.3    2.1±0.3 0.362
    Amount of infused intravenous albumin (mg) 400.4±0.6 423.3±0.8 388.8±3.2 0.436
TIPS, transjugular intrahepatic portosystemic shunt; RA, refractory ascites; INR, international normalized ratio; WBC, white blood cell; SAAG, serum asci-
tes albumin gradient; HBV, hepatitis B virus.
Variables are expressed as mean±SD or n (%).
*Portosystemic shunt procedure included peritoneo-venous shunt and transjugular intrahepatic portosystemic shunt.
†Renal failure was defined as acute or chronic renal failure, but not hepatorenal syndrome.
Table 2. Independent Predictors of RA Development in Patients with HBV-Related Liver Cirrhosis Who Were Hospitalized to 
Control Ascitic Decompensation (n=199)
Variables 
Univariate       Multivariate
p value p value            Hazard ratio 95% CI
Previous history of HE 0.025 0.092 2.841 0.845-9.560
Serum
  Sodium (mEq/L) 0.014 0.196 0.950 0.879-1.027
  Potassium (mEq/L) 0.013 0.013 2.800 1.166-6.722
HBV, hepatitis B virus; CI, confidence interval; HE, hepatic encephalopathy; RA, refractory ascites.
-2 log likelihood=102.212 (p value=0.002).
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line characteristic between survivors and non-survivors ex-
cept poorer liver function in non-survivors than survivors 
(Child-Pugh C class, 91.7 vs. 25.0%; p=0.027) (Table 3). 
All 4 survivors and 7 (58.3%) non-survivors had the diuret-
ic-resistant type of RA.
In a multivariate Cox regression analysis, Child-Pugh 
class and RA type were found to be independent predictors 
for survival in patients with RA (p=0.045; HR, 8.079; 95% 
CI, 1.231-67.984 and p=0.013; HR, 14.510; 95% CI, 1.771-
118.874, respectively) (Table 4). The median survival was 
significantly better in patients in Child-Pugh class B than 
those in Child-Pugh class C [median 13.9 (range, 7.5-51.3) 
vs. 8.3 (range, 3.9-39.8) months; log-rank test, p=0.034] 
(Fig. 2). Patients with the diuretic-resistant type of RA had 
a significantly better median survival than those with the di-
uretic-intractable type [median 13.9 (range, 4.1-51.3) vs. 
5.6 (range, 3.9-8.7) months; log-rank test, p=0.002] (Fig. 3).
Causes of mortality
Of 183 patients without RA, 157 (85.8%) had died by the 
end of follow-up. The most common causes of mortality 
those with serum potassium <4.1 mEq/L.
Clinical characteristics at the time of diagnosis of RA 
Sixteen (8.0%) patients developed RA in a median of 4.2 
(range, 1.0-39.2) months, regardless of medical therapy or 
repeated paracentesis after admission for controlling ascitic 
decompensation. Table 3 shows the clinical characteristics 
at the time of diagnosis of RA. Their mean age was 55.7 
years with a male predominance (n=13, 81.3%). Eleven 
(68.7%) patients had diuretic-resistant RA, and the other 5 
(31.3%) had diuretic-intractable RA. For managing patients 
with RA, large-volume paracentesis was repeatedly per-
formed for 2 (12.5%) patients, whereas peritoneo-venous 
shunt and TIPS were performed for 6 (37.5%) and 8 (50.0%) 
patients, respectively.
Predictors for survival in patients with RA
We compared the clinical characteristics at the time of RA 
diagnosis between 4 patients with RA who were alive (sur-
vivors) and 12 who were dead (non-survivors) at the end of 
follow-up period. There was no significantly different base-
Fig. 1. Kaplan-Meier estimate of RA development according to serum po-
tassium levels in patients with HBV-related cirrhosis who were hospital-
ized to control ascitic decompensation. The incidence of RA is significantly 
higher in patients with serum potassium ≥4.1 mEq/L than in those with <4.1 
mEq/L. RA, refractory ascites; HBV, hepatitis B virus.
Fig. 2. The cumulative survival rates according to Child-Pugh class in pa-
tients with RA. The median survival of patients with Child-Pugh B is signifi-
cantly better than those with Child-Pugh C [median 13.9 months (range, 7.5-
51.3) vs. 8.3 months (range, 3.9-39.8); log-rank test, p=0.034]. RA, refractory 
ascites.
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Table 4. Independent Predictors of Overall Survival in Patients with Refractory Ascites (n=16)
Variables 
Univariate Multivariate
p value p value Hazard ratio 95% CI
Child Pugh class, C vs. B 0.065 0.045 8.079 1.231-67.984
Refractory ascites type
    Diuretic-intractable vs. resistance type 0.007 0.013 14.510   1.771-118.874
Complications at time of RA development 
    Hepatorenal syndrome 0.036 0.359 0.382 0.049-2.983
CI, confidence interval; RA, refractory ascites.
-2 log likelihood=40.358 (p value=0.003). Reference values are Child-Pugh class B and diuretic-resistance type.
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with Child-Pugh C liver function,10,21 Child-Pugh class in 
our study was not found to be a significant predictor of RA 
development even in the univariate analysis. However, be-
cause a previous history of HE to indicate decreased liver 
function with portal hypertension showed borderline statis-
tical significance for predicting RA development in the 
multivariate analysis, poor liver function seems to affect 
RA development to a certain extent.
Electrolyte imbalances in patients with liver cirrhosis, 
such as hyponatremia or hyperkalemia, are associated with 
severe ascites, as indicated by high prevalence of RA.22,23 
Bernardi, et al.24 and Angeli, et al.25 showed a relationship 
between serum electrolyte levels and responsiveness of asci-
tes to diuretic therapy. They found that patients who do not 
respond to diuretics have lower serum sodium and higher 
potassium concentrations than those who do respond to di-
uretics. Additionally, several reports have proposed that se-
rum potassium level may affect RA development in part.22,26 
Similarly, our study showed that the risk of developing RA 
was significantly related to a higher serum potassium level 
in patients with ascitic decompensation. Although serum 
sodium concentration is known to have a significant corre-
lation with the survival of cirrhosis patients awaiting for 
liver transplantation,23,27 its role in the prediction of RA de-
velopment has not been clear. In our study, a low sodium 
level was not found to be a significant predictor of RA de-
velopment, although it was significant in a univariate analy-
sis (p=0.014).
Underlying liver function, reflected by Child-Pugh class, 
was an independent predictor for survival in patients with 
were end-stage liver disease (n=108, 68.8%), followed by 
variceal bleeding in 28, progression of HCC in 6, septic 
shock in 12, and pneumonia in 3 patients. Of 16 patients 
with RA, 12 died by the end of follow-up and their causes 
of mortality were variceal bleeding in 4 (33.3%), HRS in 3 
(25.0%), pneumonia in 3 (25.0%), and septic shock in 2 
(16.7%) patients.
DISCUSSION
Refractory ascites is an infrequent condition, and only 5-10% 
of cirrhotic patients are admitted to a hospital due to severe 
ascites that does not respond to diuretics or complications 
that preclude the administration of adequate doses of diuret-
ics.5,15 Among our 199 patients with HBV-related cirrhosis 
who were hospitalized to control ascitic decompensation, 16 
(8.0%) patients developed RA regardless of medical inter-
ventions. Recently, a similar incidence of RA (5-10%) among 
patients with liver cirrhosis was reported.15 Because we cal-
culated survival time only after admission without consid-
ering the treatment period for ascites in out-patient clinic, 
the relatively poorer median survival time of 10.7 months 
can be explained.
At least 40% of patients with responsive ascites are ex-
pected to survive for 5 years.16 In contrast, recent studies re-
ported a poor prognosis after RA development, and the 1- 
and 2-year survival probabilities of patients with RA were 
only 50-52% and 30%, respectively, without liver transplan-
tation.10,17 Thus, liver transplantation is recommended as the 
first and most important management of all cirrhotic patients 
with RA.10 However, liver transplantation is not a readily 
available procedure, and even if these patients wait for a 
long time, they may never reach the top of the transplant list. 
Repeated large volume paracentesis with albumin infusion, 
peritoneo-venous shunt, and TIPS are frequently performed 
to control RA while waiting for a liver transplant, although 
the efficacy and survival benefit of these treatment modali-
ties are controversial.18-20 Thus, the identification of predic-
tors that can select a subgroup of patients with liver cirrhosis 
who will experience RA, carries important meaning in es-
tablishing the priority of prompt liver transplantation.
In this study, serum potassium level was identified as the 
only independent predictor of RA development, while a 
previous history of HE showed borderline significance 
(p=0.092). Although some studies showed that liver failure 
was probably sufficient for RA development in patients 
Fig. 3. The cumulative survival rates according to RA type in patients with 
RA. The median survival of patients with diuretic-resistant type RA is signif-
icantly better than those with diuretic-intractable type RA [median 13.9 
months (range, 4.1-51.3) vs. 5.6 months (range, 3.9-8.7); log-rank test, p= 
0.002]. RA, refractory ascites.
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between hyperkalemia and the use of spironolactone, we 
failed to unravel the role of hyperkalemia independent of 
spironolactone, because of heterogenous treatment period 
and various total cumulative dose of spironolactone in our 
study population.
In conclusion, we found in the present study that the prog-
nosis became poor after RA development, and that serum 
potassium level was the only significant predictor of RA 
development in patients with HBV-related liver cirrhosis 
who were hospitalized to control ascitic decompensation. 
Furthermore, we demonstrated that Child-Pugh class and 
RA type significantly affected survival after RA develop-
ment. However, future prospective studies should assess 
whether serum potassium level can be used to establish the 
priority of liver transplantation in these patients. 
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